RABVACCINE company was founded in March 2018 and established in the departments of Paris, Essonne, and Aube. It is a manufacturer of tuberculosis/leprosy/meningitis vaccines and anti-cancer drugs for bladder cancer. It has determined its objectives and quality policy to set up the quality management system.

RABVACCINE manufacturers cancer drugs and vaccines. The manufacturing site is located in department 10 (Aube) in Grand Est (France) region and is under construction according to the CGMP standards in France and Europe. Our BCG vaccine (against tuberculosis/leprosy/meningitis) is designed from a French strain (BCG Pasteur).

Our Objective is the manufacture of high efficiency vaccines at competitive prices, making them accessible to the greatest number, whether it is to the ministries of health, as well as to international organizations such as UNICEF.

RABVACCINE has a very determined Mission to fight tuberculosis, a disease that still kills more than a million people each year today.

We have the high technology of manufacturing BCG at lower cost and high quality. We can manage production costs to cover not only the needs of France but also to enter the markets of other continents, especially those countries. Africans and South America.

With the use of exceptional know-how in industrial culture (surface culture) of BCG, RABVACCINE has produced and distributed more than 20 million doses of BCG vaccine against tuberculosis and 150,000 vials of BCG Endovesical for BCG- superficial bladder cancer therapy in Asia. It is developing its US patents formulated at the Institut Pasteur Paris to manufacture new anti-cancer products against invasive bladder cancer, colon cancer, and inflammatory bowel disease (IBD). The fresh culture preparation of BCG in the log phase for hospital urologists/oncologists is a new service provided by RABVACCINE for the first time in Europe.

Since 2014, there has been a significant shortage of BCG products, especially for Endovesical BCG. The demand for BCG Endovesical in 2016 is six million doses, while the total world production is 1.8 million doses. BCG Endovesical is the first choice of treatment for superficial bladder cancer, with a therapy cost ten times less than that of chemotherapy of the same efficacy.

Our Activity

• In November 2016, we equipped an L2 laboratory (Class D clean room) at Genopole (Campus 1) in Evry, to carry out R&D on the formulation and for the development of quality control tests for large-scale of manufacturing BCG products.

• After a year of work and meetings with experts in Europe and around the world, our project was studied and evaluated by KPMG France.  

• The Commissioner General for Equal Territories (CGET) reviewed and approved our project for an establishment in Aube. We are going to create 44 permanent positions and around thirty fixed-term positions.

• Based on the qualities and characteristics accepted by GMP standards in France and in Europe, our factory is under construction in a 4,000 m² building in the industrial zone of Plancy-l'Abbaye (10380) on a plot of 2.2 hectares. This building has 2,000 m² of clean room with a production capacity of 100 million doses of BCG and 500 miles from Endovesical dose of BCG.

• The design of our complex includes the construction of five well-equipped laboratories for quality control, giving us the possibility of a scientific collaboration with universities and graduate schools of Great East.